Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02805075 · ClinicalTrials.gov registry record · Phase 1
Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
A Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Recurrent Hematologic Malignancy, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02805075: Completed Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Recurrent Hematologic Malignancy, sponsored by Stanford University.
NCT02805075 is a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Recurrent Hematologic Malignancy that has completed, run by Stanford University. The registered enrollment target is 15 participants, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02805075, a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Recurrent Hematologic Malignancy, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot phase I trial studies the side effects and best dose of fructooligosaccharides in treating patients with blood cancer who are undergoing donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Nutritional supplements such as fructooligosaccharides may reduce the incidence of graft-versus-host disease in patients with blood cancer undergoing donor stem cell transplant.
Primary Outcome
Will employ the Bayesian optimal interval design.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Fructooligosaccharide
Study Locations (1)
California
- Stanford University, School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-11-17 |
| Phase | Phase 1 |
What the finished NCT02805075 record still lists
NCT02805075 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02805075 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02805075 about?
NCT02805075 is a clinical study titled "Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant". This pilot phase I trial studies the side effects and best dose of fructooligosaccharides in treating patients with blood cancer who are undergoing donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-vers...
What is the current status of trial NCT02805075?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-06. Estimated completion is 2017-11-17.
What conditions does trial NCT02805075 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Hematologic Malignancy.
What interventions are being tested in trial NCT02805075?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Fructooligosaccharide (OTHER).
Who is sponsoring clinical trial NCT02805075?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02805075 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02805075's enrollment target sits among peer trials
15 96th of 104 higher than 9 of 104 other Hematopoietic and Lymphoid Cell Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematopoietic and Lymphoid Cell Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia